Significant Ownership of Valetudo Therapeutics LLC

Signature - Title
/s/ Chris Kim - Chris Kim, Chief Executive Officer
Location
La Palma, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Valetudo Therapeutics LLC.

Notify me when Valetudo Therapeutics LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Valetudo Therapeutics LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LIMN Liminatus Pharma, Inc. Common Stock 24% 6,169,406 Valetudo Therapeutics LLC 30 Apr 2025

Schedules 13D/G Reported by Valetudo Therapeutics LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.